Provention Bio Inc. Stock News

RED BANK, N.J., Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man

Provention Bio Inc (PRVB) shares closed today at 0.7% above its 52 week low of $5.55, giving the company a market cap of $354M. The stock is currently down 67.0% year-to-date, down 67.7% over the past 12 months, and up 16.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 27.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 5333.2% The company's stock price performance over the past 12 months lags the peer average by 2988.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Wall Street brokerages forecast that Provention Bio, Inc. (NASDAQ:PRVB) will report sales of $710,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Provention Bios earnings. The highest sales estimate is $1.00 million and the lowest is $500,000.00. The business is expected to issue its next quarterly earnings report []

Provention Bio (NASDAQ:PRVB) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $7.75 price objective on the stock. Zacks Investment Researchs price target would suggest a potential upside of 20.16% from the stocks current price. []

Provention Bio (NASDAQ:PRVB) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Friday, Zacks.com reports. The firm currently has a $7.75 price target on the stock. Zacks Investment Researchs target price would suggest a potential upside of 12.48% from the companys current price. According to []

Equities analysts expect that Provention Bio, Inc. (NASDAQ:PRVB) will announce earnings of ($0.44) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Provention Bio’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.42). Provention Bio reported earnings per share of ($0.58) in the same quarter […]

Provention Bio, Inc. (NASDAQ:PRVB) CEO Ashleigh Palmer bought 3,750 shares of the companys stock in a transaction on Tuesday, November 30th. The stock was purchased at an average cost of $6.66 per share, for a total transaction of $24,975.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []

Equities analysts forecast that Provention Bio, Inc. (NASDAQ:PRVB) will announce $710,000.00 in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Provention Bios earnings. The lowest sales estimate is $500,000.00 and the highest is $1.00 million. The company is scheduled to report its next quarterly earnings results on Thursday, [] The post Provention Bio, Inc. (NASDAQ:PRVB) Expected to Post Quarterly Sales of $710,000.00 appeared first on ETF Daily News .

During the last session, Provention Bio Inc. (NASDAQ:PRVB)s traded shares were 0.59 million, with the beta value of the company hitting 2.83. At the end of the trading day, the stocks price was $7.02, reflecting an intraday loss of -5.01% or -$0.37. The 52-week high for the PRVB share is $20.05, that puts it down Provention Bio Inc. (NASDAQ: PRVB) Surged 12.32% In 6 Months Heres What To Expect Next Read More »

Sumitomo Mitsui Financial Group upgraded shares of Provention Bio (NASDAQ:PRVB) from a neutral rating to an outperform rating in a research report report published on Tuesday morning, Price Targets.com reports. PRVB has been the subject of a number of other research reports. SVB Leerink reaffirmed a buy rating and set a $16.00 price objective on []

Zacks Investment Research cut shares of Provention Bio (NASDAQ:PRVB) from a buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to Zacks, Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The companys product []

UBS Group upgraded shares of Provention Bio (NASDAQ:PRVB) from a neutral rating to an outperform rating in a report published on Tuesday morning, The Fly reports. Several other research analysts have also weighed in on PRVB. HC Wainwright restated a buy rating and set a $25.00 price objective on shares of Provention Bio in a []

The consensus price target hints at a 167.3% upside potential for Provention Bio, Inc. (PRVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn

In the last trading session, 1.26 million shares of the Provention Bio Inc. (NASDAQ:PRVB) were traded, and its beta was 2.83. Most recently the companys share price was $7.18, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $473.23M. PRVB currently trades at a Why Provention Bio Inc. (NASDAQ: PRVB) Is A Stock Not To Be Discarded In 2021 Read More »

Provention Bio, Inc. (PRVB) with the stream of 21.47% also noticed, India United Microelectronics Corporation (UMC) encountered a rapid change of 1.58% in the last hour of Mondays trading session. The post Stock that saw a surge of activity: Provention Bio, Inc. (NASDAQ:PRVB), United Microelectronics Corporation (NYSE:UMC) appeared first on Stocks Equity .